Trial Profile
A phase I/II trial to investigate the safety and efficacy of rituximab and intravenous immunoglobulin (IVIG) as agents to desensitize highly human leukocyte antigen (HLA) sensitized dialysis patients awaiting kidney transplantation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 17 Jul 2008 Results have been published in the New England Journal of Medicine.
- 10 Apr 2008 New trial record.